The study aimed to investigate the real-world efficacy and safety of the Ram plus pac combination as a 2L treatment for advanced GC/GEJC. Ram plus pac demonstrates significant survival benefits similar to RAINBOW study findings, with no new safety concerns in real-world use. Ramucirumab plus paclitaxel combination (Ram/Pac) has been established as a […]...
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Advertisement
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a transformative treatment for various hematological malignancies. Still, its remarkable efficacy is accompanied by unique adverse events that must be carefully managed. This comprehensive literature review …
Objectives: Breast cancer is the most diagnosed cancer in women, with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) being the predominant subtype. Sacituzumab govitecan (SG), a novel antibody-drug conjugate, has emerged as a promising …
Objectives: For many malignancies, hypofractionated radiotherapy (HFRT) is an accepted standard associated with decreased treatment time and costs. United States provider beliefs regarding HFRT likely impact its adoption but are poorly studied. We surveyed US-based …
Objective: This systematic review and meta-analysis aims to evaluate the efficacy and safety of bevacizumab in patients with ovarian cancer over a shorter and longer follow-up period. Methods: We searched Medline, Cochrane CENTRAL, Scopus, and Google …
